VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer
Abstract
The aim of the present study was to evaluate the levels of VEGF, 8-isoprostane and TNF-α in EBC and serum of patients with primary lung cancer prior to the initiation of any treatment, in order to evaluate their possible diagnostic role. Furthermore, associations between VEGF, 8-isoprostane and TNF-α levels in EBC and serum with clinicopathologic factors were investigated.
We enrolled 30 patients with lung cancer (mean age 65.2
±
10.5 years) and 15 age and gender-matched healthy smokers as controls. Serum and EBC were collected before any treatment. TNF-α, VEGF and 8-isoprostane levels in EBC and serum were analyzed by an immunoenzymatic method (ELISA).
A statistically significant difference was observed between lung cancer patients and the control group regarding the values of TNF-α, both in EBC (52.9
±
5.0
pg/ml vs. 19.4
±
3.9
pg/ml, p
<
0.0001) and serum (44.5
±
6.3
pg/ml vs. 22.2
±
4.3
pg/ml, p
=
0.035). Moreover, EBC VEGF levels were higher in patients with T3–T4 tumor stage compared to T1–T2 (9.3
±
2.8
pg/ml vs. 2.3
±
0.7
pg/ml, p
=
0.047). A statistically significant correlation was also observed between serum and EBC values of VEGF (r
=
0.52, p
=
0.019). In addition, serum levels of VEGF were higher in lung cancer patients than in controls (369.3
±
55.1
pg/ml vs. 180.5
±
14.7
pg/ml, p
=
0.046). VEGF serum levels were also found higher in patients with advanced stage of disease (IIIB–IV) and distant nodal metastasis (N2–N3). No differences were observed in 8-isoprostane in EBC between lung cancer patients and controls. In contrast, serum 8-isoprostane levels were higher in lung cancer patients compared to controls (24.9
±
3.6
pg/ml vs. 12.9
±
1.6
pg/ml, p
=
0.027) and were higher in patients with advanced disease. All three biomarkers presented acceptable reproducibility in the EBC on two consecutive days.
In conclusion, we have shown that TNF-α, VEGF and 8-isoprostane are elevated in the serum of lung cancer patients and increased serum VEGF and 8-isoprostane levels are related to advanced disease. In EBC, increased TNF-α levels were observed in lung cancer patients, whereas increased VEGF levels were observed in advanced T-stage. Further longitudinal studies are warranted for the evaluation of the prognostic role of these biomarkers in lung cancer.
Abbreviations: EBC, exhaled breath condensate, VEGF, vascular endothelial growth factor, TNF-α, tumor necrosis factor alpha, ROS, reactive oxygen species, BAL, bronchoalveolar lavage
Keywords: TNF-α, VEGF, 8-Isoprostane, Oxidative stress, Biomarkers, Exhaled breath condensate, Lung cancer
To access this article, please choose from the options below
PII: S0169-5002(08)00461-3
doi:10.1016/j.lungcan.2008.08.015
© 2008 Elsevier Ireland Ltd. All rights reserved.
